#
Antagonism Between DUX4 and DUX4c Highlights a Pathomechanism Operating Through β-Catenin in FSHD
Dec 17, 2022
New Publication from Grant Recipient: Professor Zammit at King's College
#
SEAHAWKS Tickets - Bid today and Enjoy this Sold Out Game Dec. 15th
Nov 14, 2022
Here's YOUR chance to attend a Seahawks game and support FSHD research at the same time!
#
A Letter from Dr. Robert Bloch
Oct 31, 2022
A thank you letter from Dr. Bloch.
#
Progress Update: Novel Therapeutics for FSHD: Mitochondria-targeted Antioxidants
Oct 28, 2022
Final report of year one.
#
Request for Proposals for FSH Muscular Dystrophy Research
Oct 16, 2022
Friends of FSH Research is calling for grant proposals now for final submission by the end of January 2023 with funding in March 2023.
#
Progress Update: Testing the effects of antifibrotic drugs on an FSHD mouse model and FSHD fibroadipoprogenitors: the first step toward antifibrotic therapy for FSHD
Oct 11, 2022
Final update by Dr. Bosnakovski.
#
Pilot Funding Makes a Difference
Oct 4, 2022
The mission of Friends of FSH Research is to accelerate research that will help find a treatment or cure for FSH muscular dystrophy. This strategy sometimes requires us to fund unique, novel and potentially risky research pilot projects.
#
CTRN Quarterly Newsletter
Aug 23, 2022
FSHD Clinical Trial Research Network Quarterly Newsletter - Summer 2022
#
Seat Elevation Systems as an Accessory to Power Wheelchairs (Group 3)
Aug 23, 2022
CMS has accepted a formal request to consider both the benefit category and coverage for seat elevation systems and standing systems.
#
Update: Tongue electro-impedance myography: a window into FSHD
Aug 4, 2022
Dr. Sanchez provides a final update on his novel tongue EIM assessment device.
#
Update: Generation of a craniofacial muscle model of FSHD
Aug 4, 2022
Final udpate from Dr Guo on the generation of a craniofacial muscle model of FSHD from iPSCs.
#
Update: Determining in vitro and in vivo efficacy of novel DUX4 inhibitors
Aug 4, 2022
Dr. Ozes provides a brief update on progress in testing quite novel DUX4 inhibitors.
#
Update: Motor Outcomes to Validate Evaluations in FSHD
Aug 4, 2022
Update on MOVE FSHD study.
#
Progress Update: Regulation and activity of the DUX4 transcription factor
May 13, 2022
Final report from Dr. Tapscott on his multi-year grant program.
#
Progress Update: Deciphering the role of aberrant protein synthesis in FSHD
May 8, 2022
Dr. Jagannathan provides a final research report.
#
Progress Update: Molecular Mechanism of p38 Kinase-mediated inhibition of DUX4
May 5, 2022
Final report from Dr. Rajanikanth Vangipurapu.
#
2022 FSHD Research Update Meeting - Video
Mar 23, 2022
Video of 2022 Research Update Meeting.
#
Master Builders Association - Free Ramp Building
Mar 5, 2022
Rampathon 2022 - Building wheelchair access ramps in King and Snohomish Counties for free.
#
Fulcrum Therapeutics® Announces REACH, a Phase 3 Clinical Trial of Losmapimod in FSHD
Mar 3, 2022
Fulcrum Therapeutics, Inc. announced its plans to initiate REACH, a Phase 3 clinical trial of losmapimod in people with FSHD, in the second quarter of 2022.
#
Progress Update: In vivo model to validate drugs targeting DUX4 enhancer/promoter activity
Mar 1, 2022
Dr. Hiramuki provides a final project update.